Home Newsfeeds Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

byBenzinga Newsdesk

October 17, 2022

1 minute read

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $55

By Benzinga Newsdesk

August 10, 9:25 AM

Morgan Stanley analyst Vikram Purohit maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $54 to $55.

AXSM

Parsons’ Strength Of New Contracts Trigger Upgrade By This Analyst; Predicts Upside Of Over 20% Next Year

By Shivani Kumaresan

March 28, 2:20 PM

William Blair analyst Louie DiPalma upgraded Parsons Corp (NYSE:PSN) from Market Perform to Outperform. The analyst’s dotted Line contract tracker uncovered that…

PSN

S&P 500 Could Build On 2023’s 24% Gain: Analyst Shares Key Data Supporting Continued Broader Market Performance

By Shanthi Rexaline

January 1, 12:55 PM

Stocks finished 2023 with stellar gains, helped by rate-cut expectations. The resilient economy and the market gains could continue in 2024.

IWO

Analyst Ratings

Barclays Maintains Equal-Weight Rating for CPSI: Here’s What You Need To Know

By Benzinga Insights

January 22, 1:00 PM

Barclays has decided to maintain its Equal-Weight rating of CPSI (NASDAQ:CPSI) and lower its price target from $12.00…

CPSI

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Related Posts

Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $55

Parsons’ Strength Of New Contracts Trigger Upgrade By This Analyst; Predicts Upside Of Over 20% Next Year

S&P 500 Could Build On 2023’s 24% Gain: Analyst Shares Key Data Supporting Continued Broader Market Performance

Barclays Maintains Equal-Weight Rating for CPSI: Here’s What You Need To Know